GR 63799Alternative Names: GR 63799X
Latest Information Update: 13 Jun 2002
At a glance
- Originator GlaxoSmithKline
- Developer GlaxoSmithKline; Nonindustrial source
- Class Antiulcers
- Mechanism of Action Prostaglandin agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Peptic ulcer; Reperfusion injury